Opinion statement
Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Gronchi A, Casali PG, Mariani, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21:1390–7.
Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors. Cancer. 1999;86:2045–52.
Pritchard DJ, Nascimento AG, Petersen IA. Local control of extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1996;78-A:848–54.
Molloy AP, Hutchinson B, O'Toole GC. Extra-abdominal desmoid tumours: a review of the literature. Sarcoma. 2012;2012:1–9.
Escobar C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol. 2012;23:562–9.
Mankin HJ, Hornicek FJ, Springfield DS. Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol. 2010;102:380–4.
Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor: not a benign disease. Arch Surg. 1989;124:191–6.
Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984;66:1369–74.
Okuno SH. The enigma of desmoid tumors. Curr Treat Options Oncol. 2006;7:438–43.
McDougall A, McGarrity G. Extra-abdominal desmoid tumours. J Bone Joint Surg Br. 1979;61-B:373–7.
Mullen JT, DeLaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19:4028–35. Analysized prognostic factors of surgically treated desmoid tumors. Reported the goal of surgically treated desmoid tumors is function-sparing surgery with wide excision with negative margins when possible. Adjuvant radiation therapy was used selectively to improve local control in patients with positive margins.
Weiss SW, Goldblum JR, Enzinger FM. Enzinger and Weiss's soft tissue tumors. In: Weiss SW, Goldblum JR, editors. Fibromatoses. 5th ed. Philadelphia: Mosby Elsevier; 2001. p. 227–56.
Soule EH, Scanlon PW. Fibrosarcoma arising in an extraabdominal desmoid tumor: report of case. Mayo Clin Proc. 1962;37:443.
Bonvalot S, Desai A, Coppola S, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012;23:158–66. Proposed a treatment algorithm with more conservative approach to treatment.
Biermann JS. Desmoid tumors. Curr treat options oncol. 2000;1:262–6.
Lucas DR, Shroyer KR, McCarthy PJ, et al. Desmoid tumor is a clonal cellular proliferation: PCR amplification of HUMARA for analysis of patterns of X-chromosome inactivation. Am J Surg Pathol. 1997;21:306–11.
Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785–91.
Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29:3553–8. Demonstrated that in select subgroup of patients (desmoid tumors in non-threatening locations or at risk for mutilating surgery), observation resulted in stable or regressive disease in 21/27 patients. Although, 6/27 patients had progressive disease, all patient stabilized by the end of their follow-up.
Lazar A, Tuvin D, Hajibashi S, et al. Specific mutations in the β- catenin gene ( CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.
Kasper B, Dimitrakopoulou-Strauss A, Strauss LG, et al. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imaging. 2010;37:1876–82.
von Mehren M, Benjamin RS, Bui MM, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:951–60. Reported updated guidelines in the management of desmoid tumors.
Leithner A, Gapp M, Leithner K, et al. Margins in extra-abdominal desmoid tumors: a comparative analysis. J Surg Oncol. 2004;86:152–6.
Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.
Leibel SAS, Wara WMW, Hill DRD, et al. Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9:1167–71.
Nuyttens JJ, Rust PF, Thomas CR, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors. Cancer. 2000;88:1517–23.
Fontanesi JJ, Mott MPM, Kraut MJM, et al. The role of postoperative irradiation in the treatment of locally recurrent incompletely resected extra-abdominal desmoid tumors. Sarcoma. 2004;8:83–6.
Rutenberg MS, Indelicato DJ, Knapik JA, et al. External-beam radiotherapy for pediatric and young adult desmoid tumors. Pediatr Blood Cancer. 2010;57:435–42.
Kujak JL, Liu PT, Johnson GB, et al. Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol. 2010;39:175–82.
Clark TW. Percutaneous chemical ablation of desmoid tumors. J Vasc Interv Radiol. 2003;14:629–33.
Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40:637–45.
Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.
Conflicts of Interest
Brian E. Walczak declares that he has no conflicts of interest.
Peter S. Rose declares that he has no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Walczak, B.E., Rose, P.S. Desmoid: The Role of Local Therapy In an Era of Systemic Options. Curr. Treat. Options in Oncol. 14, 465–473 (2013). https://doi.org/10.1007/s11864-013-0235-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-013-0235-7